Budapest, Hungary

Qualiclinic

Rheumatoid Arthritis

Arthritis

Systemic Lupus Erythematosus

Autoimmune Diseases

Joint Diseases

Collagen Diseases

Immune System Diseases

Musculoskeletal Diseases

Rheumatic Diseases

Connective Tissue Diseases

GLPG0634

Baricitinib

Methotrexate

LY3471851

KPL-404

Peresolimab

Galapagos

Lilly

Kiniksa Pharmaceuticals

Nektar Therapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Qualiclinic | Budapest, Hungary

Site insights

Work at this site?

Active trials

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)

Trial sponsors